All News
Filter News
Found 808,690 articles
-
Aethlon Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.
-
Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
8/9/2022
Fore Biotherapeutics, today announced that data from the ongoing Phase 1/2a study of lead asset, FORE8394, will be presented in the Developmental Therapeutics poster session at the European Society of Medical Oncology Congress (ESMO) taking place in Paris, France, September 9-13, 2022.
-
MannKind Corporation Reports 2022 Second Quarter Financial Results
8/9/2022
MannKind Corporation reported financial results for the second quarter and first half of 2022.
-
InMed Announces Changes to its Board of Directors
8/9/2022
InMed Pharmaceuticals Inc. is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.
-
908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook
8/9/2022
908 Devices Inc. today reported financial results for the quarter ended June 30, 2022.
-
BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance
8/9/2022
BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, announced financial results for the three and six months ended June 30, 2022.
-
NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode
8/9/2022
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration ("FDA") on August 8th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.
-
Cohen Children’s Medical Center unveils $110M Pediatric Surgical Operating Complex
8/9/2022
Cohen Children’s Medical Center announced the opening of the Pediatric Surgical Operating Complex, a $110 million, 24,000-square-foot, state-of-the-art home for pediatric surgery that greatly enhances the capabilities of New York State’s No. 1 provider of pediatric health services and largest Level 1 pediatric trauma center.
-
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
8/9/2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.
-
Public Advisory - Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled because it may contain particulate matter
8/9/2022
Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.
-
Avenda Health Receives FDA Investigational Device Exemption for AI-enabled Prostate Cancer Therapy
8/9/2022
Avenda Health, an AI healthcare company creating the future of prostate cancer care, today announced its FocalPoint ablation system powered by iQuest, a patient management AI software, has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA).
-
Seer Reports Second Quarter 2022 Financial Results
8/9/2022
Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the second quarter ended June 30, 2022.
-
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
8/9/2022
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, announced financial results and recent highlights for the second quarter ended June 30, 2022.
-
Novanta Announces Financial Results for the Second Quarter 2022
8/9/2022
Novanta Inc. today reported financial results for the second quarter 2022.
-
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
8/9/2022
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), today announced that it has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin its 15 patient study evaluating REM-001 Photodynamic Therapy (PDT) for the treatment of Cutaneous Metastatic Breast Cancer (CMBC).
-
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
8/9/2022
Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update.
-
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
8/9/2022
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates.
-
CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)
8/9/2022
CalciMedica Inc. ("CalciMedica" or the "Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of preclinical data in EMBO Molecular Medicine that describes the potential utility for CRAC channel inhibitors in inflammatory bowel disease (IBD).
-
Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
8/9/2022
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it's Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy.
-
CooperCompanies Appoints Nicholas Khadder as General Counsel and Corporate Secretary
8/9/2022
CooperCompanies announced that Nicholas Khadder has been appointed as its general counsel and corporate secretary.